Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E79.15 EPS (ttm)2.29 Insider Own0.10% Shs Outstand255.70M Perf Week4.17%
Market Cap46.29B Forward P/E29.81 EPS next Y6.07 Insider Trans-69.47% Shs Float255.50M Perf Month4.63%
Income594.90M PEG1.94 EPS next Q1.08 Inst Own97.90% Short Float1.44% Perf Quarter-1.54%
Sales3.27B P/S14.18 EPS this Y99.10% Inst Trans0.76% Short Ratio2.92 Perf Half Y12.23%
Book/sh18.47 P/B9.80 EPS next Y39.71% ROA- Target Price208.86 Perf Year15.62%
Cash/sh13.60 P/C13.31 EPS next 5Y40.75% ROE- 52W Range145.37 - 195.81 Perf YTD9.24%
Dividend- P/FCF- EPS past 5Y23.90% ROI11.20% 52W High-7.55% Beta1.41
Dividend %- Quick Ratio3.70 Sales past 5Y20.30% Gross Margin86.70% 52W Low24.52% ATR4.35
Employees2500 Current Ratio3.80 Sales Q/Q34.00% Oper. Margin- RSI (14)59.87 Volatility2.51% 2.40%
OptionableYes Debt/Eq0.00 EPS Q/Q27.00% Profit Margin- Rel Volume0.51 Prev Close183.97
ShortableYes LT Debt/Eq0.12 EarningsJul 30 AMC Payout- Avg Volume1.26M Price181.02
Recom1.90 SMA204.81% SMA505.11% SMA2001.82% Volume641,824 Change-1.60%
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jun-24-19 10:05AM  Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children Zacks
Jun-22-19 08:00AM  3 Stocks That Could Double Your Money Motley Fool
Jun-21-19 02:30PM  FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene Business Wire
10:01AM  3 Big Biotechs Hold Growth Potential in Second Half of 2019 Zacks
Jun-20-19 07:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $9.8 million of Shares GuruFocus.com
09:38AM  The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper Zacks
08:31AM  Check Out These 5 Fast-Growing Stocks to Buy Today InvestorPlace
Jun-19-19 02:02PM  Top Stock Reports for Deere, Las Vegas Sands & Vertex Zacks
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
09:00AM  Glaxo Inks Genome Research Deal With University of California Zacks
07:22AM  3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics InvestorPlace
Jun-13-19 10:47AM  Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray American City Business Journals
Jun-12-19 09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
08:15AM  5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit Motley Fool
Jun-11-19 09:30AM  CELG or VRTX: Which Is the Better Value Stock Right Now? Zacks
Jun-10-19 08:20PM  Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy? Insider Monkey
09:29AM  CRISPR Therapeutics Up on Collaboration Expansion by Vertex Zacks
Jun-09-19 12:15PM  3 Healthcare Stocks I'd Buy Right Now Motley Fool
07:27AM  Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy? Motley Fool
Jun-07-19 05:14PM  Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing Investor's Business Daily
04:43PM  Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend traders to sell the rally Yahoo Finance Video
09:54AM  Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion Benzinga
09:54AM  Vertex Pharmaceuticals Bets on Gene Therapy With New Acquisition Barrons.com
09:24AM  Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
Jun-06-19 06:37PM  Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals Reuters
06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
05:12PM  Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics Business Wire
Jun-05-19 09:44AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne Zacks
Jun-04-19 02:12PM  5 Biotech Stocks to Buy Right Now Zacks
08:00AM  Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF Business Wire
Jun-03-19 12:16AM  Watertown biotech Lyndra snags longtime Vertex exec as CEO American City Business Journals
Jun-02-19 09:52AM  Should You Be Excited About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 45% Return On Equity? Simply Wall St.
May-31-19 08:25AM  Vertex Selects Triple Combo Regimen for Regulatory Submission Zacks
May-30-19 04:09PM  This Biotech Just Inched Closer To Treating 90% Of Cystic Fibrosis Patients Investor's Business Daily
02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
02:17PM  KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns definitive ratings to Five CMBS classes of KNDL 2019-KNSQ Mortgage Trust Moody's
09:31AM  Why Is Vertex (VRTX) Down 3.5% Since Last Earnings Report? Zacks
08:54AM  Vertex to file for approval of cystic fibrosis therapy in 2019 Reuters
08:00AM  Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis Business Wire
May-29-19 04:24PM  5 Pharmaceutical Stocks With Big Moats and Bridges Kiplinger
01:39PM  3 Large-Cap Stocks With Superior Performances GuruFocus.com
May-28-19 08:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $19.9 million of Shares GuruFocus.com
May-26-19 09:00AM  3 Big Biotech Stocks That Warren Buffett Might Like Motley Fool
May-24-19 09:30AM  CELG or VRTX: Which Is the Better Value Stock Right Now? Zacks
May-22-19 11:34AM  Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN Zacks
May-19-19 02:00PM  Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
May-15-19 11:04AM  Atlas-backed Kymera signs deal with Vertex worth up to $1B American City Business Journals
08:30AM  Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases Business Wire
May-13-19 09:27AM  5 Growthy Biotech Stocks to Buy Despite the Scrutiny InvestorPlace
May-12-19 09:00AM  Here's My Top Stock to Buy in May Motley Fool
May-09-19 07:07AM  New England Venture Capital Association names 2019 NEVY Awards winners American City Business Journals
May-08-19 07:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $5.8 million of Shares GuruFocus.com
03:56PM  The Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Has Gained 155%, So Why Not Pay It Some Attention? Simply Wall St.
12:24PM  KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns provisional ratings to five CMBS classes of KNDL 2019-KNSQ Mortgage Trust Moody's
09:30AM  CELG vs. VRTX: Which Stock Should Value Investors Buy Now? Zacks
09:15AM  Trade Anxieties Return with a Vengeance Zacks
08:27AM  Why CRISPR Therapeutics Gained 13.4% in April Motley Fool
May-07-19 10:47AM  Proteostasis (PTI) to Post Q1 Earnings: What's in Store? Zacks
May-02-19 03:47PM  Vertex Pharmaceuticals Looks to Jump From 18,000 Patients to 68,000 Motley Fool
11:47AM  Edited Transcript of VRTX earnings conference call or presentation 30-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
11:18AM  The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks
10:00AM  Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
08:15AM  5 Things You Need to Know From Vertex Pharmaceuticals' Q1 Earnings Update Motley Fool
May-01-19 11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
11:46AM  Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates Zacks
03:36AM  Vertex Pharmaceuticals Inc (VRTX) Q1 2019 Earnings Call Transcript Motley Fool
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
05:30PM  Cystic Fibrosis-Focused Biotech Easily Tops First-Quarter Estimates Investor's Business Daily
04:17PM  Vertex: 1Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports First-Quarter 2019 Financial Results Business Wire
01:00PM  Health Care Stocks: Buy Them While They're Down Kiplinger
12:06PM  Vertex Earnings, Revenue Beat in Q1 Investing.com
08:30AM  FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age Business Wire
Apr-29-19 04:45PM  Insulin-maker Eli Lilly is scheduled to report earnings Tuesday. Heres what to expect MarketWatch
01:42PM  Beaten-down health-care companies join Apple and Google in earnings parade MarketWatch
01:41PM  Merck is reporting earnings on Tuesday. Heres what to expect MarketWatch
10:10AM  Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report? Zacks
Apr-28-19 05:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Apr-24-19 04:32PM  What's in Store for Vertex (VRTX) This Earnings Season? Zacks
03:01PM  Everything You Need to Know About Investing in Healthcare Motley Fool
09:15AM  Solid Earnings Boost S&P, NASDAQ to New Closing Highs Zacks
Apr-23-19 10:32AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
08:44AM  2 Best Biotech Buyout Plays Motley Fool
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
11:02AM  5 Top Healthcare Stocks to Buy in 2019 Motley Fool
Apr-17-19 03:10PM  Dow Jones Falls As Medical Stocks Massacred, But Top Stocks Thrive In This Sector Investor's Business Daily -7.10%
10:18AM  Qualcomm's 23% one-day stock surge is a rarity for the market CNBC
07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:18PM  CRISPR Therapeutics Attempts Breakout on FDA Fast Track Investopedia
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia GlobeNewswire
Apr-15-19 07:47AM  Heres one way to tell if a company is overpaying its CEO MarketWatch
Apr-12-19 08:00AM  Vertex to Announce First-Quarter 2019 Financial Results on April 30 Business Wire
Apr-11-19 08:23AM  Has Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Got Enough Cash? Simply Wall St.
Apr-09-19 11:07AM  Why Vertex Pharmaceuticals Could Conceivably Succeed Too Well Motley Fool
09:53AM  5 Stocks in the Age of Miracles Motley Fool
09:27AM  The 10 Fastest-Growing Stocks to Invest In Right Now InvestorPlace
Apr-04-19 01:38PM  Biotech, in motion: Demand for life science execs fuels game of musical chairs American City Business Journals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Option Exercise131.892,125280,26635,365Jun 20 04:53 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Sale181.892,125386,51633,240Jun 20 04:53 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Option Exercise77.3156,0304,331,679162,317Jun 20 04:43 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Sale175.3956,0309,827,054106,287Jun 20 04:43 PM
Bhatia Sangeeta N.DirectorJun 03Sale167.08720120,2986,540Jun 04 04:08 PM
Parini MichaelEVP, CL&AOMay 30Sale173.00707122,31135,625May 06 04:08 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Option Exercise77.31113,4328,769,428219,719May 28 05:45 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Sale175.10113,43219,861,943106,287May 28 05:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale165.419115,05231,553May 17 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale165.4113322,00033,240May 17 04:18 PM
Kewalramani ReshmaEVP and CMOMay 15Sale165.4124139,86413,736May 17 04:21 PM
Parini MichaelEVP, CL&AOMay 15Sale165.418313,72935,003May 17 04:29 PM
Silva Paul MSVP & ControllerMay 15Sale165.4116126,63117,759May 17 04:31 PM
Sachdev AmitEVP, CROMay 15Sale165.416110,09033,416May 17 04:37 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Option Exercise77.3133,0582,555,714136,953May 08 04:10 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Sale175.0133,0585,785,504106,195May 08 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Option Exercise86.521,553134,36634,793May 06 04:06 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,329201,50537,332May 06 04:08 PM
Parini MichaelEVP, CL&AOMay 03Sale172.061,622279,07435,003May 06 04:08 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Sale172.391,553267,72333,240May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Option Exercise91.052,155196,21335,395May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Sale169.272,155364,76833,240May 06 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Option Exercise77.3110,480810,209116,375May 03 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Sale175.0810,4801,834,826106,195May 03 04:06 PM
Parini MichaelEVP, CL&AOApr 16Option Exercise111.736,375712,27939,253Apr 18 04:12 PM
Parini MichaelEVP, CL&AOApr 16Sale181.996,3751,160,16635,003Apr 18 04:12 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 15Sale181.755,6241,022,14833,240Apr 17 04:30 PM
Parini MichaelEVP, CL&AOFeb 19Sale186.985,6241,051,58535,003Feb 21 04:26 PM
Silva Paul MSVP & Interim CFOFeb 19Sale186.972,812525,74717,759Feb 21 04:27 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 19Sale187.005,6241,051,71631,553Feb 21 04:21 PM
Kewalramani ReshmaEVP and CMOFeb 19Sale186.941,488278,16313,736Feb 21 04:22 PM
LEIDEN JEFFREY MCEO & PresidentFeb 19Sale186.9820,9973,926,113106,195Feb 21 04:24 PM
Silva Paul MSVP & Interim CFOFeb 11Sale180.164,215759,36720,571Feb 13 04:27 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 11Sale180.2133,0735,959,96938,864Feb 13 04:37 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale180.2232,9565,939,18837,177Feb 13 04:36 PM
Sachdev AmitEVP, CROFeb 11Sale180.0635,0956,319,21640,165Feb 13 04:40 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale180.24111,43120,083,804127,192Feb 13 04:39 PM
Silva Paul MSVP & Interim CFOFeb 06Option Exercise91.051,289117,36313,938Feb 07 04:04 PM
Silva Paul MSVP & Interim CFOFeb 06Sale193.001,289248,77712,649Feb 07 04:04 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Option Exercise99.977,959795,65754,711Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Option Exercise88.904,097364,23548,817Feb 06 04:51 PM
Parini MichaelEVP, CL&AOFeb 04Option Exercise86.522,330201,59238,489Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Option Exercise88.494,126365,11741,443Feb 06 04:46 PM
Silva Paul MSVP & Interim CFOFeb 04Option Exercise86.5280969,99516,896Feb 06 04:49 PM
LEIDEN JEFFREY MCEO & PresidentFeb 04Sale186.3532,2506,009,682124,865Feb 06 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Sale189.194,126780,59839,113Feb 06 04:46 PM
Parini MichaelEVP, CL&AOFeb 04Sale189.192,330440,81336,159Feb 06 04:45 PM
Sachdev AmitEVP, CROFeb 04Sale186.8612,7222,377,29638,037Feb 06 04:51 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Sale186.2018,3093,409,08236,402Feb 06 04:50 PM
Silva Paul MSVP & Interim CFOFeb 04Sale187.024,247794,27312,649Feb 06 04:49 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Option Exercise131.892,125280,26641,238Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Option Exercise131.892,125280,26648,877Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Option Exercise155.573,668570,63143,277Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Sale193.482,125411,14539,113Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Sale193.482,125411,14546,752Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Sale195.003,668715,26039,609Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Option Exercise155.701,223190,42140,336Jan 22 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Sale194.621,223238,02039,113Jan 22 04:07 PM
Silva Paul MSVP & Corp ControllerJan 17Option Exercise90.623,007272,48217,376Jan 18 04:18 PM
Silva Paul MSVP & Corp ControllerJan 17Sale190.623,007573,18216,087Jan 18 04:18 PM
Parini MichaelEVP, CL&AOJan 14Option Exercise90.292,125191,86641,734Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 14Sale186.712,125396,75939,609Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 04Option Exercise122.454,250520,41343,859Jan 07 04:02 PM
Parini MichaelEVP, CL&AOJan 04Sale165.904,250705,07539,609Jan 07 04:02 PM
SACHS BRUCE IDirectorDec 06Option Exercise34.2410,000342,40023,011Dec 07 04:06 PM
Silva Paul MSVP & Corp ControllerDec 03Option Exercise86.5280969,99516,896Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerDec 03Sale186.52809150,89516,087Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerNov 15Sale163.75121,96516,087Nov 19 05:52 PM
Parini MichaelEVP, CL&AONov 15Sale163.759014,73839,609Nov 19 05:47 PM
Sachdev AmitEVP, CRONov 15Sale163.75619,98946,662Nov 19 05:34 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale163.75294,74946,752Nov 19 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale163.7510016,37539,113Nov 19 05:23 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Option Exercise86.522,330201,59241,443Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 05Option Exercise86.521,941167,93548,603Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Option Exercise103.095,803598,21151,002Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Option Exercise86.522,330201,59241,939Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Sale173.731,941337,20446,662Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Sale172.085,803998,58046,752Nov 06 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Sale172.082,330400,94639,113Nov 06 04:11 PM
Parini MichaelEVP, CL&AONov 05Sale172.082,330400,94639,609Nov 06 04:32 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Option Exercise91.051,796163,52640,909Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Option Exercise91.052,155196,21348,817Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Option Exercise91.052,155196,21348,907Nov 05 04:52 PM
Sachdev AmitEVP, CRONov 02Sale172.862,155372,50546,662Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Sale175.361,796314,94739,113Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Sale175.362,155377,90146,752Nov 05 04:52 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86641,734Oct 16 04:29 PM
Parini MichaelEVP, CL&AOOct 12Sale177.202,125376,55039,609Oct 16 04:29 PM
Kewalramani ReshmaEVP and CMOOct 08Sale186.952,305430,9201,909Oct 09 04:50 PM
Parini MichaelEVP, CL&AOOct 04Option Exercise122.454,250520,41343,859Oct 05 05:35 PM
Parini MichaelEVP, CL&AOOct 04Sale191.584,250814,21539,609Oct 05 05:35 PM
Bhatia Sangeeta N.DirectorOct 03Option Exercise126.386,818861,6509,579Oct 05 05:28 PM
Bhatia Sangeeta N.DirectorOct 03Sale192.136,8181,309,9424,879Oct 05 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Option Exercise155.572,445380,36941,558Oct 02 04:30 PM
Graney ThomasChief Financial OfficerOct 01Sale193.241,076207,92612,430Oct 02 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Sale194.622,445475,84639,113Oct 02 04:30 PM